Wall Street Zen Downgrades Immix Biopharma (NASDAQ:IMMX) to Sell

Immix Biopharma (NASDAQ:IMMX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

IMMX has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Mizuho initiated coverage on Immix Biopharma in a research note on Monday, February 9th. They set an “outperform” rating and a $14.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $11.00.

Immix Biopharma Stock Performance

Shares of Immix Biopharma stock opened at $7.33 on Friday. The firm has a market cap of $388.20 million, a PE ratio of -9.52 and a beta of 0.31. The firm’s 50-day simple moving average is $5.74 and its 200-day simple moving average is $3.88. Immix Biopharma has a 1 year low of $1.34 and a 1 year high of $7.73.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Marshall Wace LLP raised its holdings in shares of Immix Biopharma by 3,495.4% during the fourth quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after buying an additional 1,923,708 shares during the last quarter. Bleichroeder LP increased its position in Immix Biopharma by 17.6% in the 4th quarter. Bleichroeder LP now owns 1,000,000 shares of the company’s stock valued at $5,230,000 after acquiring an additional 150,000 shares during the period. Hudson Bay Capital Management LP acquired a new stake in Immix Biopharma in the 4th quarter valued at approximately $176,000. Jane Street Group LLC raised its stake in Immix Biopharma by 1,016.4% during the 4th quarter. Jane Street Group LLC now owns 167,132 shares of the company’s stock valued at $874,000 after acquiring an additional 152,162 shares in the last quarter. Finally, Tocqueville Asset Management L.P. grew its stake in shares of Immix Biopharma by 70.3% in the fourth quarter. Tocqueville Asset Management L.P. now owns 68,550 shares of the company’s stock worth $359,000 after purchasing an additional 28,300 shares in the last quarter. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.